The not-so innocent bystander: the microenvironment as a therapeutic target in cancer

被引:34
|
作者
Erickson, AC [1 ]
Barcellos-Hoff, MH [1 ]
机构
[1] Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA
关键词
basement membrane; breast cancer; extracellular matrix (ECM); microenvironment; stroma; TGF-beta;
D O I
10.1517/eott.7.1.71.21161
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The microenvironment in which cancer arises is often regarded as a bystander to the clonal expansion and acquisition of malignant characteristics of the tumour. However, a major function of the microenvironment is to suppress cancer, and its disruption is required for the establishment of cancer. In addition, tumour cells can further distort the microenvironment to promote growth, recruit non-malignant cells that provide physiological resources, and facilitate invasion. In this review, the authors discuss the contribution of the microenvironment, i.e., the stroma and its resident vasculature, inflammatory cells, growth factors and the extracellular matrix (ECM), in the development of cancer, and focus on two components as potential therapeutic targets in breast cancer. First, the ECM, which imparts crucial signalling via integrins and other receptors, is a first-line barrier to invasion, modulates aggressive behaviour and may be manipulated to provide novel impediments to tumour growth. Second, the authors discuss the involvement of TGF-beta1 as an example of one of many growth factors that can regulate ECM composition and degradation and that play complex roles in cancer. Compared to the variable routes taken by cells to become cancers, the response of tissues to cancer is relatively consistent. Therefore, controlling and eliminating cancer may be more readily achieved indirectly via the tissue microenvironment.
引用
收藏
页码:71 / 88
页数:18
相关论文
共 50 条
  • [21] The axon in Guillain-Barre syndrome: Immune target or innocent bystander?
    Powell, HC
    Myers, RR
    ANNALS OF NEUROLOGY, 1996, 39 (01) : 4 - 5
  • [22] 'Dysfunctional' adipose tissue in cardiovascular disease: a reprogrammable target or an innocent bystander?
    Antoniades, Charalambos
    CARDIOVASCULAR RESEARCH, 2017, 113 (09) : 997 - 998
  • [23] Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target
    Hartupee, Conner
    Nagalo, Bolni Marius
    Chabu, Chiswili Y.
    Tesfay, Mulu Z.
    Coleman-Barnett, Joycelynn
    West, John T.
    Moaven, Omeed
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [24] Aminosalicylates and colorectal cancer in IBD: A not-so bitter pill to swallow
    Ryan, BM
    Russel, MGVM
    Langholz, E
    Stockbrugger, RW
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (08): : 1682 - 1687
  • [25] Lung amyloidosis: Innocent bystander, or novel target-organ in transthyretin amyloidosis?
    Banydeen, Rishika
    Monfort, Astrid
    Inamo, Jocelyn
    Neviere, Remi
    RESPIRATORY MEDICINE, 2022, 197
  • [26] Microalbuminuria in Type 2 Diabetes and Hypertension A marker, treatment target, or innocent bystander?
    Basi, Seema
    Fesler, Pierre
    Mimran, Albert
    Lewis, Julia B.
    DIABETES CARE, 2008, 31 : S194 - S201
  • [27] Influence of Exercise on Inflammation in Cancer: Direct Effect or Innocent Bystander?
    Murphy, E. Angela
    Enos, Reilly T.
    Velazquez, Kandy T.
    EXERCISE AND SPORT SCIENCES REVIEWS, 2015, 43 (03): : 134 - 142
  • [28] PATHOLOGIC LESIONS OF GVH DISEASE IN HAMSTER - ANTIGENIC TARGET VERSUS INNOCENT BYSTANDER
    STREILEIN, JW
    PROGRESS IN EXPERIMENTAL TUMOR RESEARCH, 1972, 16 : 396 - +
  • [29] Mechanistic target of rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer
    Liu, Yueze
    Feng, Mengyu
    Chen, Hao
    Yang, Gang
    Qiu, Jiangdong
    Zhao, Fangyu
    Cao, Zhe
    Luo, Wenhao
    Xiao, Jianchun
    You, Lei
    Zheng, Lianfang
    Zhang, Taiping
    CANCER LETTERS, 2020, 485 : 1 - 13
  • [30] Apoptotic cell clearance in the tumor microenvironment: a potential cancer therapeutic target
    Seong-Ah Shin
    Sun Young Moon
    Daeho Park
    Jong Bae Park
    Chang Sup Lee
    Archives of Pharmacal Research, 2019, 42 : 658 - 671